

The Pallium Project  
le projet Pallium



Working Together to Improve the Quality of  
Living and Dying in Canada

Travailler ensemble pour améliorer la qualité  
de la vie et de la fin de vie au Canada

---

## Pallium Palliative Pocketbook (PPP)

Index and Errata (Version 1.0 – First Printing, Sept 2008)

---

Released June 2009

Copies of this index document are available at no-cost in PDF format at  
[www.pallium.ca/infoware/PPP-1\\_Index&Errata\\_June2009.pdf](http://www.pallium.ca/infoware/PPP-1_Index&Errata_June2009.pdf)

## Introduction

First released in September 2008, the Pallium Palliative Pocketbook (PPP) is used widely throughout Canada's provinces and territories to inform point-of-care decision-making in service of the seriously ill and dying and as a reminder/reinforcement tool for various learning and development initiatives. As of June 2009, some 9,000 units are confirmed to be in circulation in eleven of Canada's thirteen provinces and territories.

Consistent with a commitment to continuous improvement, an errata identification process was established with book circulation. Moreover, in early 2009 at the request of many users serving as regional palliative care coordinators, nurse consultants, physician consultants and tertiary-palliative care unit service providers, an indexing project was undertaken by the publication team.

The following index has been purposefully designed to assist the busy palliative services professional provide quick topic and problem identification, especially to provide telephone and in-person support to primary-care colleagues. This index is also designed in an 8" x 11" format suitable for printing and storage in a binder at nursing units/station desks, primary care physician community offices and consultant offices.

An electronically tagged version of this index will be available in the Pallium Palliative Pocketbook (Version 1.1) e-book version, scheduled for release at [www.palliativetools.info](http://www.palliativetools.info) in August 2009.

## Notice of Errata

The following errata have been identified by the publication team during detailed reviews of the Pallium Palliative Pocketbook (1.0). No other errata have been reported to-date by end-users. Note:

Page Number (vers1.0)	Description	Suggested Remediation
5-11	Figure 5-1 WHO Ladder for Pain Control Severe Pain is mislabeled/double labeled as Step 2 rather than Step 3.	- Remaining books in any local inventory - change Step 2 to Step 3 with a black pen - Book holders - change to Step 3 w/black pen
12-1	(see <i>Supportive counseling</i> on page 12-14),	(see Supportive counseling on page 12-4), - cross out the 1 in 12-14, to read 12-4
12-7	Spelling error of Mirtazepine 2/3 down page in sub-section starting - Consider SSRIs...	- cross out e and change to Mirtazapine
16-2	Spelling error of Mirtazepine in last subsection on page, starting, - Responds to dialysis...	- cross out e and change to Mirtazapine
16-3	Spelling error of Mirtazepine under Malignancy and Opioids bulleted sections.	- cross out e and change to Mirtazapine

# Index

5-HT<sub>3</sub> antagonists 8–11  
  granisetron 8–3, 8–11  
  ondansetron 8–3, 8–11  
  tropisetron 8–11

## A

Acetaminophen 5–11, 5–13, 5–14,  
  5–15, 5–56, 5–80, 5–88, 9–4,  
  12–19, 16–4  
Acetylsalicylic Acid 5–80  
Acute dystonia 7–15  
Acute grief 20–2  
Addiction 5–2, 5–3, 5–18, 5–19,  
  5–52  
Adjustment disorder 12–3, 12–12  
Adjuvant Analgesics 5–54  
  NSAIDs 5–56  
  corticosteroids 5–57, 5–67  
  bisphosphonates 5–58  
  anticonvulsants 5–64  
  gabapentin 5–64  
  carbamazepine 5–65  
  tricyclic antidepressants 5–66  
Adjuvant analgesics and therapies  
  used in the management of  
  neuropathic pain 5–62  
Adjuvant analgesics and therapy  
  options for bone pain 5–55,  
  5–56  
Adjuvants 5–11, 5–56 to 5–71  
Adrenal insufficiency 8–2, 8–6,  
  10–10  
  cortisone 10–10  
  fludrocortisone 10–10  
Agitation 5–30, 5–57, 7–1, 7–5,  
  7–12, 12–18 to 12–21  
Airway secretions 15–6, 19–3  
Akathisia 7–11, 7–15, 12–18  
Alginates 9–17  
Allodynia 5–6, 5–30, 5–86  
Alpha-2-adrenergic agonists 5–62  
Aluminum astringents 9–17  
Aminocaproic acid 6–23, 9–19  
Amitriptyline 5–67, 12–16, 12–17,  
  12–23

Amyotrophic Lateral Sclerosis (ALS)  
  15–1  
  airway secretions 15–6  
  artificial feeding 15–4, 15–5  
  dysarthria 15–5  
  dysphagia 15–4  
  dyspnea 15–4  
  Maximal Inspiratory Pressure  
    15–2  
  nocturnal oximetry 15–2  
  non-invasive positive pressure  
    ventilation 15–2  
  non-invasive ventilation 15–3  
  respiratory support 15–2  
  tracheostomy 15–3  
  vital capacity 15–2, 15–5  
Anemia 6–11, 9–1  
  anemia, microcytic 9–2  
  anemia, normocytic 9–2  
  anemia, macrocytic 9–2  
  blood transfusions 9–3  
  recombinant human  
    erythropoietin 9–4  
Anesthetic procedures 5–73  
  bupivacaine 5–73  
  celiac plexus blocks 5–73  
  nerve blocks 5–73  
  spinal blocks 5–73  
Anorexia 8–27. *See also* Cachexia  
  appetite stimulation 8–31  
  artificial feeding 8–35  
  cannabinoids 8–33  
  corticosteroids 8–32  
  dietary omega-3 polyunsaturated  
    fatty acids 8–32  
  feeding 8–35  
  inflammatory cytokines 8–27  
  megesterol acetate 8–31  
  olanzapine 8–33  
  thalidomide 8–33  
Antibiotic guidelines 16–7  
Anticholinergic (antimuscarinic)  
  agents 8–24  
Anticipatory grief 20–2  
Anticonvulsants 5–64

Intro ■

Contents ■

1 ■  
Principles

2 ■  
Ethics

3 ■  
Communicate

4 ■  
Expectancy

5 ■  
Pain

6 ■  
CP

7 ■  
Delirium

8 ■  
GI

9 ■  
Hematology

10 ■  
Metabolic

11 ■  
Neurological

12 ■  
Psychological

13 ■  
Spiritual

14 ■  
Emergencies

15 ■  
Non-Cancer

16 ■  
Miscellaneous

17 ■  
Interventions

18 ■  
Sedation

19 ■  
Terminal

20 ■  
Grief

Appendix ■

Refs ■

Anticonvulsant therapy 11-1, 11-5  
 Antidepressants 5-66, 8-1, 12-15,  
 12-17, 12-22  
 antidepressant, selecting an  
 12-25  
 Antiemetic 5-29, 8-3  
 methotrimeprazine 7-12, 8-10  
 refractory nausea 8-12  
 Antifibrinolytic agents 6-23, 9-19  
 Antihistamines 8-11, 16-2  
 Antimicrobials 16-8  
 Antitussives 6-21  
 Anxiety disorders 12-5  
 Aphthous ulceration. *See* Stomatitis  
 8-48  
 Appetite stimulation 8-30, 8-31  
 Artificial feeding 8-35, 15-4  
 Artificial hydration 17-15  
 ethical issues 2-11  
 edema, discontinuation 6-30  
 bowel obstruction 8-22  
 sc administration 17-6  
 Artificial nutrition 8-34  
 ALS 15-5  
 dysphagia 8-38  
 ethical issues 2-11  
 NG 8-34  
 patient concerns 8-30  
 PEG tube 8-34  
 temporary use 8-26, 18-30  
 ASA 5-11. *See* Acetylsalicylic acid  
 Ascites 8-36  
 diuretics 8-37  
 paracentesis 8-36, 8-37  
 peritoneovenous shunt 8-37  
 Aspiration pneumonia 16-12  
 complications 15-4, 15-5  
 Assisted suicide 2-12, 17-2  
 Ataxia/tremor 15-8  
 Atropine 6-25  
 Atypical antidepressants 12-19,  
 12-23  
 Atypical neuroleptics 7-9, 8-11  
 olanzapine 7-13  
 Autonomy 2-8, 2-11, 3-18

## B

Baclofen 5-62, 5-68, 6-26, 15-6,  
 15-7  
 Bad news 3-5  
 Barium 8-21, 8-40  
 Bedside Confusion Scale (BCS) 7-5  
 Benzodiazepines 5-29, 6-14, 7-10,  
 7-15, 12-8, 12-28  
 Bereavement 20-1  
 BiPaP. *See* Non-invasive Positive  
 Pressure Ventilation, 6-15,  
 15-2  
 Bisacodyl 8-16  
 Bisphosphonates 5-58, 10-3  
 hypercalcemia 10-3  
 sedation 18-2  
 side effects 5-60  
 skeletal events 5-58  
 Bleeding 9-15  
 alginates 9-17  
 aluminum astringents 9-17  
 aminocaproic acid 6-23, 9-19  
 antifibrinolytic agents 9-19  
 coagulation factors 9-20  
 collagen-based hemostats 9-17  
 endoscopy 8-41, 9-18  
 epinephrine 9-16  
 epistaxis 9-16, 9-17  
 fibrin sealants 9-18  
 formalin 9-17  
 Fresh Frozen Plasma 9-9, 9-19,  
 9-20  
 from bladder 9-18  
 gastrointestinal (GI) bleeding  
 5-81, 8-41, 9-20  
 gelatin-based hemostats 9-17  
 hemoptysis 6-17, 6-22, 8-41,  
 9-18, 14-6  
 liver failure 9-19  
 lower GI bleeding 8-42  
 massive bleeding 14-6  
 octreotide 9-20  
 oxidized cellulose 9-17  
 platelets 9-20  
 prostaglandins E2 and F2 9-18  
 sclerotherapy 9-18  
 sucralfate suspension 9-17

surgery 9–19  
 surgical absorbable hemostatic dressings 9–17  
 thrombocytopenia 9–19  
 thromboplastin 9–17  
 topical cocaine 9–17  
 tranexamic acid 6–23, 9–12, 9–16, 9–19  
 transcutaneous arterial embolization or balloons 9–19  
 variceal bleeding 9–18  
 vasopressin 9–20  
 vena caval filters 6–28, 9–11  
**Blessed Orientation Memory Concentration Test (BOMC)** 7–4, A–12  
**Blood transfusions** 8–42, 9–3  
**Bone pain** 5–54  
 bisphosphonates 5–58, 10–3  
 clodronate 5–58  
 corticosteroids 5–67  
 pamidronate 5–58  
 skeletal events 5–58  
 zoledronic 5–58  
**Bowel obstruction**  
 anticholinergic (antimuscarinic) agents 8–24  
 antihistamines 8–11  
 chronic partial 8–27  
 constipation management 8–16  
 contraindication, metoclopramide 8–9, 8–22  
 corticosteroids 8–24  
 functional/paralytic ileus 8–26  
 haloperidol 8–10  
 hyoscine butylbromide 8–24  
 irreversible 8–26  
 malignant 8–18  
 obstipation 8–13  
 octreotide 8–24  
 potentially reversible 8–23  
 somatostatin analogue 8–24  
 surgical management 8–25  
 venting PEG tube 8–26  
**Bowel stimulant** 8–15, 8–26  
**Brain death** 17–1

**Brain metastases** 5–29, 7–2, 11–4, 12–20, 14–7  
**Breakthrough pain** 5–5, 5–10, 5–14, 5–26, 5–49  
 OTFC formulation 5–24, 5–49  
 sublingual fentanyl 5–50  
 sufentanyl 5–50  
**Breakthroughs** 5–10, 5–27, 5–34  
**Bronchitis** 16–13  
**Bronchorrhoea** 6–22  
 glycopyrrolate 6–22  
 hyoscine hydrobromide 6–22  
**Bronchoscopy** 6–7, 6–17  
**Buccal route** 5–24, 5–49, 5–84, 8–40  
**Buddhism** 13–14  
**Bupivacaine** 5–73  
**Bupropion** 12–20, 12–23  
**Buscopan** 5–70, 6–25, 8–12, 8–22, 8–45

## C

**Cachexia** 8–27  
 appetite stimulation 8–31  
 artificial feeding 8–35  
 artificial nutrition 8–34  
 cannabinoids 8–33  
 corticosteroids 8–32  
 dietary omega-3 polyunsaturated fatty acids 8–32  
 distinguished from starvation 8–28  
 feeding 8–35  
 inflammatory cytokines 8–27, 8–28  
 megesterol acetate 8–31, 8–33  
 olanzapine 8–33  
 thalidomide 8–33  
**Calcium gluconate** 10–8  
**Calgary Guidelines (palliative sedation)** 18–5  
**Candida** 8–46, 16–15  
 esophageal 8–46  
 oral 8–46  
**Cannabinoids** 5–71, 8–12, 8–33  
**Capsaicin topical** 5–62, 5–67  
**Carbamazepine** 5–15, 5–62, 5–65, 11–3, 15–7

Intro	■
Contents	■
1	■
Principles	
2	■
Ethics	
3	■
Communicate	
4	■
Expectancy	
5	■
Pain	
6	■
CP	
7	■
Delirium	
8	■
GI	
9	■
Hematology	
10	■
Metabolic	
11	■
Neurological	
12	■
Psychological	
13	■
Spiritual	
14	■
Emergencies	
15	■
Non-Cancer	
16	■
Miscellaneous	
17	■
Interventions	
18	■
Sedation	
19	■
Terminal	
20	■
Grief	
Appendix	■
Refs	■

- Carcinoid 8–18
- Cauda equina. *See* Spinal cord compression 14–2
- Celiac plexus blocks 5–62, 5–73
- Cellulitis 6–30, 16–10, 17–22
- Cerebral metastases 11–4
- Chlorpromazine 6–14, 6–26, 7–9, 8–10
- Christianity 13–10
- Chronic Obstructive Pulmonary Disease (COPD) 15–11
- Cimetidine 16–2, 16–3
- Citalopram 12–18, 12–22, 12–25
- Clodronate 5–58, 5–59, 5–60, 10–4, 17–7
- Clonazepam 5–62, 5–76, 12–7, 12–11
- Clonidine 5–62
- Coagulation factors 9–20
- Codeine 5–11, 5–14, 5–21, 5–25, 5–47, 5–88, 6–13, 6–21, 12–17, 17–9
- Code status 3–18, 3–19
- Cognitive impairment 5–9
  - BOMC test A-12
  - cerebral metastases 11–4
  - delirium 7–1
  - decision capacity 2–6
  - driving (opioids) 5–20
  - opioid neurotoxicity 5–30
  - pain assessment 5–9
- Collagen-based hemostats 9–17
- Communication 3–1
  - advance care planning 3–17
  - breaking bad news 3–5
  - code status 3–18
  - denial 3–21
  - dignity 3–27
  - dignity-conserving care 3–27
  - disclosure 3–1
  - Do Not Resuscitate (DNR) 3–18
  - eliciting concerns 3–14
  - empathy 3–10, 3–15
  - family conference 3–23
  - FIFE 3–14
  - futility 3–18
  - goals of care 3–13
  - hope 3–16
  - How long do I have to live? 3–22
  - SPIKES 3–6
  - truth telling 3–1
- Community acquired pneumonia 16–11, 16–12
- Complicated grief 20–5
- Confusion 5–30
  - delirium 7–1
  - hypercalcemia 10–1
  - hyponatremia 10–6
  - neurotoxicity 5–30
  - TCA's, elderly 12–17
- Confusion Assessment Method 7–5
- Congestive heart failure 4–5
  - edema 6–29
  - hyperkalemia, managing 10–8
  - midazolam, clearing 18–8
- Constipation 5–28, 8–13
  - bisacodyl 8–16
  - bowel stimulant 8–15
  - constipation score 8–15
  - docusate 8–15, 8–16
  - enemas 8–17
  - fleet enema 8–16
  - lactulose 8–15, 8–16, 8–44
  - magnesium citrate 8–17, 8–26
  - manual dis-impaction 8–17
  - micro-enema 8–16
  - oil retention enema 8–16
  - oral fleet 8–16, 8–17
  - osmotic laxative 8–15
  - senna-based laxative 6–13, 8–15, 8–16
  - sodium phosphate 8–16, 8–17
  - stool softener 8–15, 8–18
  - suppositories 8–17, 8–45
- Constipation Score 8–15
- Contrast studies 8–21
- Controlled-release 5–37
  - end-of-dose failure 5–38
- COPD 4–6, 5–25, 5–35, 6–13, 6–15, 6–21, 15–11. *See also* Chronic Obstructive Airway Disease
- Cordotomy 5–55, 5–62, 5–74
- Corticosteroid myopathy 6–4, 6–11

Corticosteroids 5–57, 5–62, 5–63,  
5–67, 5–70, 8–12, 8–24, 8–32,  
11–4, 11–6, 14–4

Cortisone 10–10

Cough 6–20  
antitussives 6–21  
inhaled sodium cromoglycate  
6–21  
lidocaine 6–21  
nebulizer 6–21

Coumadin 9–8. *See* Warfarin

CPR 3–18

Cultural influences 3–3, 8–34

Cystitis 16–9

Cytochrome P450 CYP 2D6 5–14

## D

Dalteparin 9–8, 9–9, 9–10

D-dimer 9–5, 9–14, 9–15

Death certification 19–4

Death is approaching.  
*See* Terminal Phase

Death is imminent.  
*See* Terminal Phase

Death rattle. *See* Terminal  
respiratory congestion

Decision-making 2–1  
advance care planning 3–17  
disclosure 3–1  
establishing decision-making  
capacity 2–6  
ethical frameworks 2–8  
goals of care 2–1, 3–13  
proxy decision making 2–3  
withdrawing respirators 17–2

Defibrillators 2–15, 2–16

Defining palliative care 1–1  
hospice palliative care 1–5  
palliative care approach 1–2  
phases of palliative care 1–5

Dehydration 5–29, 8–46, 17–15

Delirium 7–1  
assessment 7–5  
causes 7–2  
clinical presentation 7–3  
hyperactive type 7–3

hypoactive type 7–3  
subclinical syndrome 7–3

dementia 7–4  
screening 7–4

Delirium management  
atypical neuroleptics 7–9  
chlorpromazine 7–9  
haloperidol 7–9  
lorazepam 7–16  
loxapine 7–9, 7–12  
methotrimeprazine 7–9, 7–12  
midazolam 7–16  
olanzapine 7–9, 7–13, 7–14  
psychostimulants 7–16  
quetiapine 7–9, 7–12, 7–14  
risperidone 7–9, 7–13, 7–14

Delirium screening  
Bedside Confusion Scale (BCS)  
7–5  
Blessed Orientation Memory  
and Concentration Test  
(BOMC) 7–4  
Confusion Assessment Method  
(CAM) 7–5  
Mini Mental State Examination  
(MMSE) 7–4  
Nursing Delirium Evaluation  
(NuDESC) Scale 7–5

Dementia 4–6, 7–4, 7–12

Demoralization syndrome 12–28

Denial 3–21

Depression  
amitriptyline 5–67, 12–17, 12–23  
bupropion 12–20, 12–23, 12–25  
citalopram 12–18, 12–22, 12–25  
demoralization syndrome 12–28  
desipramine 5–67, 12–17, 12–23  
dextroamphetamine 12–20,  
12–24  
electroconvulsive therapy 12–27  
fluoxetine 12–18, 12–22  
flvoxamine 12–22  
heterocyclic antidepressants  
12–21  
insomnia 12–28  
major depression disorder 12–12  
methylphenidate 5–71, 7–16,  
12–20, 12–24

Intro	■
Contents	■
1	■
Principles	
2	■
Ethics	
3	■
Communicate	
4	■
Expectancy	
5	■
Pain	
6	■
CP	
7	■
Delirium	
8	■
GI	
9	■
Hematology	
10	■
Metabolic	
11	■
Neurological	
12	■
Psychological	
13	■
Spiritual	
14	■
Emergencies	
15	■
Non-Cancer	
16	■
Miscellaneous	
17	■
Interventions	
18	■
Sedation	
19	■
Terminal	
20	■
Grief	
Appendix	■
Refs	■

- mirtazapine 12–19, 12–23, 12–25
- modafinil 12–24
- monoamine oxidase inhibitors 12–21
- nefazodone 12–20, 12–23
- nortriptyline 5–67, 12–17, 12–23
- paroxetine 5–84, 12–7, 12–9, 12–18, 12–22, 12–25, 12–26
- psychiatrist 12–27
- psychostimulants 12–20
- screening, anxiety 12–5
- screening, depression 12–12
- selecting an antidepressant in palliative care 12–25
- selective serotonin reuptake inhibitors 12–18
- serotonin – norepinephrine reuptake inhibitor (SNRI) 12–19
- sertraline 12–18, 12–22, 12–25, 15–10
- St. John's Wort 12–22
- trazodone 12–20, 12–23
- tricyclic antidepressants 5–66, 12–17, 12–23
- venlafaxine 12–19, 12–22, 12–25
- Desipramine 5–67, 12–23
- Dexamethasone 5–57, 6–9, 6–18, 11–5, 14–4, 17–7
- Dextroamphetamine 12–20, 12–24
- Dextromethorphan 5–69, 6–21
- Diabetes mellitus. See Hyperglycemia
- Diabetic chronic ulcer 16–10
- Diarrhoea 8–17
  - diphenoxylate 8–18
  - loperamide 8–18
  - stomas 8–43
- DIC. See Disseminated intravascular coagulation
- Dietary Omega-3 Polyunsaturated Fatty Acids 8–32
- Dignity 3–27, 13–1, 13–8
- Dignity Conserving Care. See Dignity 3–27, 13–8
- Dilantin. See Phenytoin
- Dimenhydrinate 8–2, 8–9, 8–12, 8–22, 17–8
- Diphenoxylate 8–18
- Disclosure 3–1
  - cultural influences 3–3
  - tasks of palliative care 1–4
- Discontinuing TD fentanyl. See fentanyl transdermal 5–38, 5–40, 5–90
- Disseminated intravascular coagulation 9–14
- Diuretics 8–37
  - ascites 8–36
  - CHF 15–10
  - edema 6–29
  - SVCS 6–19
- DNR. See *also* Do Not Resuscitate
- Docusate 8–15, 8–16
- Do Not Resuscitate 2–13, 3–18
- Dopamine antagonism 5–29
- Dorsal rhizotomy 5–74
- Doxepin 16–2
- Driving 5–20
- Drooling 8–48, 15–6
- Dry mouth 8–46, 12–17, 12–25
- Duragesic. See fentanyl transdermal
- Dysarthria 15–5
- Dyspepsia 8–38
- Dysphagia 8–38, 8–39, 15–4
- Dyspnea 6–1, 15–4
  - airway secretions 19–3
  - anemia 6–11
  - ascites 6–11
  - assessment 6–5
    - spirometry/lung function tests 6–7
- BiPaP 6–15
  - causes 6–3
- COPD patients 6–13, 15–11
- corticosteroid myopathy 6–4, 6–11
- empyema 6–9, 6–16
- heart conditions 6–11
- lymphangitic carcinomatosis 6–3, 6–9, 6–23
- management 6–8

Maximal Inspiratory Pressure 15–2  
 nocturnal oximetry 15–2  
 non-invasive positive pressure ventilation 6–15, 15–2  
 non-invasive ventilation 15–3, 15–11  
 non-invasive ventilatory support 6–15  
 obstructive airway disease 6–11  
 opioids 6–12  
 oxygen 6–13  
 pericardial effusion 6–3, 6–10, 6–18  
 phenothiazine 6–14  
 pleural effusion(s) 6–9, 6–15, 15–10  
 pneumonia 6–3, 6–5, 6–10  
 pneumothorax 6–3, 6–9  
 pulmonary artery/vein occlusion 6–3, 6–10  
 pulmonary embolism 6–3, 6–5, 6–7, 6–8, 6–10, 6–26  
 respiratory support 15–2  
 superior vena cava syndrome 6–3, 6–10, 6–19, 14–8  
 tamponade 6–3, 6–10, 6–18  
 thoracentesis 6–15, 6–16  
 tracheobronchial obstruction 6–9, 6–17  
 tracheostomy 15–3  
 vital capacity 15–2

## E

Edema 6–28, 6–30  
 diuretics 8–37  
 Edmonton Symptom Assessment System (ESAS) A–2  
 Elderly, opioid management 5–53  
 Electroconvulsive therapy 12–27  
 Emergency 14–1  
 massive bleeding 14–6  
 seizure 14–7  
 spinal cord compression 14–1  
 superior vena cava syndrome 6–19

Emesis centres 8–3  
 Empathy 3–10, 3–15, 20–4  
 Empyema 6–9, 6–16, 6–25  
 Endobronchial stenting 6–17  
 End-of-dose failure 5–38, 5–40  
 Endoscopy 9–18  
 GI bleeding 8–41  
 Enemas 8–17  
 Epidural route 5–24, 5–32, 5–51, 5–55, 5–73, 8–45, 9–7  
 Epinephrine 9–16  
 Epistaxis 9–15, 9–17  
 Ethics/ethical issues 2–1, 2–7  
 artificial hydration 2–11  
 artificial nutrition 2–11, 8–26, 8–27  
 assisted suicide 2–12, 17–2  
 beneficence 2–8  
 code status 3–18  
 euthanasia 2–12, 17–2  
 futility 2–11, 3–18  
 justice 2–8  
 non-maleficence 2–8, 2–11  
 principles of medical ethics 2–8  
 ventilation 2–11  
 withholding or withdrawing treatments 2–5, 2–11, 3–12, 5–2, 8–35, 17–2, 17–18  
 Euthanasia 2–12  
 differentiating, respirator support 17–2  
 differentiating, palliative sedation 18–1  
 Excessive sweats 16–4  
 Existential distress/issues 12–28, 13–3, 18–6  
 Extrapyrarnidal side effects (EPS) 7–14  
 acute dystonia 7–15  
 akathisia 7–15  
 combining antiemetics 8–13  
 Parkinsonism 7–15

Intro	■
Contents	■
1	■
Principles	
2	■
Ethics	
3	■
Communicate	
4	■
Expectancy	
5	■
Pain	
6	■
CP	
7	■
Delirium	
8	■
GI	
9	■
Hematology	
10	■
Metabolic	
11	■
Neurological	
12	■
Psychological	
13	■
Spiritual	
14	■
Emergencies	
15	■
Non-Cancer	
16	■
Miscellaneous	
17	■
Interventions	
18	■
Sedation	
19	■
Terminal	
20	■
Grief	
Appendix	■
Refs	■

## F

- Faith traditions 13–10
- Family conference 3–23
- Febrile neutropenic patient 16–15
- Feeding (artificial nutrition) 8–34, 15–4
- Fentanyl 5–11, 5–84
  - CSCI 5–43
  - OTFC formulation 5–24, 5–49
  - sublingual fentanyl 5–50
- Fentanyl citrate 17–8
- Fentanyl transdermal 5–38, 5–40, 5–90
  - lowest patch strength 5–38
- Fever 16–3
  - excessive sweats 16–4
  - fever with rigors 16–4
  - neutropenic infections 16–4
  - paraneoplastic fever 16–4
- Fibrin sealants 9–18
- FICA spiritual assessment tool 13–4
- FIFE 3–14
- Fistulas 8–44
- Flecainide 5–62, 5–68
- Fleet enema 8–16
- Fludrocortisone 10–10
- Fluoxetine 5–65, 12–22
- Fluvoxamine 12–22
- Formalin 9–17
- Fresh Frozen Plasma 9–9, 9–19, 9–20
- Furosemide 6–25, 6–29, 8–37, 10–7, 15–9, 17–8, 19–2
- Futility 2–11, 3–18

## G

- GABA agonists 5–62
- Gabapentin 5–62, 5–64, 15–7
- Gastrograffin 8–21
- Gastrointestinal (GI) bleeding 8–41, 8–42, 5–80, 5–81
- Gastrostomy tube 5–24, 15–5
- Gelatin-based hemostats 9–17
- Generalized Anxiety Disorder 12–5, 12–19
- Gingivostomatitis. *See* Stomatitis

- Glycopyrrolate 6–22, 6–25, 17–9
- Goals of care 2–1, 3–13
- Granisetron 8–3, 8–11
- Grief 20–1
  - acute 20–2
  - anticipatory 20–2
  - complicated 20–5
  - uncomplicated 20–1

## H

- Hallucinations 5–30, 7–3, 7–5, 11–4
- Haloperidol 7–9, 7–11, 8–3, 8–9, 8–10, 17–9, 19–2
- Heart conditions 6–11
- Heart failure 15–9
  - dyspnea 6–1
  - furosemide 15–9
  - hydrochlorothiazide 15–9
  - local anaesthetics 5–68
  - loop diuretic 15–9
  - metolazone 15–9
  - pacemakers/ICDs 2–15
  - prognosis 4–5
  - thiazide diuretic 15–9
- Hemoptysis 6–22, 9–18, 14–6, 14–7
- Hepatic failure 5–68, 6–29, 7–6, 8–44
- Herpes Zoster 16–16
- Heterocyclic antidepressants 12–21
- Hiccups 6–25
- Hinduism 13–12
- Hope 3–16, 13–1, 13–9
- Hospital acquired pneumonia 16–11
- Hot flashes 16–5
- Hyaluronidase 17–21
- Hydration 17–15
  - hyaluronidase 17–21
  - hypodermoclysis 17–19, 17–20
- Hydrochlorothiazide 15–9
- Hydromorphone 5–11, 5–25, 5–83, 5–89, 17–10
- Hyoscine butylbromide 5–70, 6–25, 8–12, 8–24, 17–10
- Hyoscine hydrobromide 6–22, 6–24, 6–25, 8–12, 16–4, 17–14

Hyperalgesia 5–30  
 Hypercalcemia 5–29, 5–58, 10–1, 17–17  
     bisphosphonate 10–3  
 Hyperglycemia 10–11  
 Hyperkalemia 10–8  
     calcium gluconate 10–8  
     kayexalate 10–8  
     polystyrene sulfonate 10–8  
     renal disease prognosis 4–7  
 Hyponatremia 10–7  
 Hypoalbuminemia 10–10  
 Hypocalcemia 10–6  
     SIADH 10–7  
 Hypodermoclysis 17–19, 17–20  
 Hypokalemia 10–9  
 Hypomagnesemia 10–9  
     magnesium gluconate/heptanate 10–9  
     magnesium sulphate 10–9  
 Hyponatremia 10–6

**I**

Illness trajectory 1–2, 2–3. *See also* Life expectancy  
 Incident pain 5–26, 5–49  
 Infection 16–5  
     antimicrobials 16–8  
     aspiration pneumonia 16–12  
     bronchitis 16–13  
     catheter, unknown sepsis 5–74  
     cellulitis 16–10  
     community acquired pneumonia 16–12  
     cystitis 16–9  
     diabetic chronic ulcer 16–10  
     diarrhoea 8–17  
     febrile neutropenic patient 16–15  
     fever and sweats 16–3  
     herpes zoster 16–16  
     hospital acquired pneumonia 16–11  
     lower respiratory tract infections 16–11  
     leucocytosis 9–13  
     lung abscess 16–13

nursing home acquired pneumonia 16–12  
 pain aggravation 5–10  
 peri-rectal cellulitis/abscess 16–10  
 peritonitis 16–14  
 pyelonephritis 16–9  
 secondary bacterial peritonitis 16–15  
 somnolence/sedation 5–29  
 stomatitis 8–47  
 urinary tract infections (UTI) 8–2, 16–9  
 urosepsis 16–10  
 Inflammatory cytokines 8–27, 16–3  
 Inhaled sodium cromoglycate 6–21  
 Insomnia 12–28  
 Interventional radiological procedures 5–74  
     interventional radiology cordotomy 5–74  
     dorsal rhizotomy 5–74  
     laminectomy 5–74  
 Intramuscular 5–24  
 Intraspinal route 5–24, 8–45  
 Intrathecal route 5–24, 8–45  
 Intravenous 17–19  
 Islam 13–11  
 IV. *See* Intravenous  
 IV Lidocaine infusions 5–68

**J**

Judaism 13–15

**K**

Kayexalate 10–8  
 Ketamine 5–62, 5–69  
 Kyphoplasty 5–74

**L**

Lactulose 8–15, 8–44  
 Laminectomy 5–74, 14–5  
 Lamotrigine 5–62, 5–65, 5–66  
 Last Days and Hours 19–1.  
     *See* Terminal Phase

Intro	■
Contents	■
1	■
Principles	
2	■
Ethics	
3	■
Communicate	
4	■
Expectancy	
5	■
Pain	
6	■
CP	
7	■
Delirium	
8	■
GI	
9	■
Hematology	
10	■
Metabolic	
11	■
Neurological	
12	■
Psychological	
13	■
Spiritual	
14	■
Emergencies	
15	■
Non-Cancer	
16	■
Miscellaneous	
17	■
Interventions	
18	■
Sedation	
19	■
Terminal	
20	■
Grief	
Appendix	■
Refs	■

## Laxatives

- bisacodyl 8–16
- bowel stimulant 8–15, 8–26
- docusate 8–15, 8–16
- enemas 8–17
- fleet enema 8–16
- lactulose 6–13, 8–15, 8–45
- magnesium citrate 8–17, 8–26
- manual dis-impaction 8–17
- micro-enema 8–16
- oil retention enema 8–16
- oral fleets 8–17
- osmotic laxative 8–15
- senna-based laxative 8–15
- sodium phosphate 8–16, 8–17
- stool softener 8–15
- suppositories 8–17
- Leptomeningeal involvement 11–6
- Leucocytopenia 9–14
- Leucocytosis 9–13
- Lidocaine 5–68, 6–21
- Lidocaine infusion 5–62, 5–68
- Lidocaine patch 5–62
- Lidocaine, topical 5–67
- Life expectancy 2–3, 4–1.  
    *See also* Prognostication
- Liver failure 8–44, 9–19
- Local anesthetics 5–68
- Loop diuretic 10–5, 15–9
- Loperamide 8–18
- Lorazepam 6–28, 7–16, 12–9,  
    12–10, 12–28, 14–7
- Lower GI bleeding 8–42
- Lower respiratory tract infections  
    16–11
- Low molecular weight heparins  
    (LMWH) 9–7
  - dalteparin 9–8
  - tinzaparin 9–8
- Loxapine 7–9, 7–12
- Lung abscess 16–13
- Lymphangitic carcinomatosis 6–3,  
    6–9
- Lymphatic obstruction 6–29, 8–36
- Lymphedema. *See* Edema

## M

- Magnesium citrate 8–17, 8–26
- Magnesium gluconate/heptanate  
    10–9
- Magnesium sulphate 10–9
- Major depression disorder.  
    *See* Depression
- Manual dis-impaction 8–17
- Massive bleeding 14–6
- Maximal Inspiratory Pressure 15–8
- Medical futility 2–11
- Medical heroism 2–5
- Medical nihilism 2–5
- Megesterol acetate 8–31
- Methadone 5–11, 5–69, 5–86,  
    5–90, 5–92
- Methotrimeprazine 7–9, 7–12,  
    8–10, 8–13, 12–28, 17–10,  
    18–7
- Methylphenidate 5–29, 7–16,  
    12–20, 12–24
- Metoclopramide 8–9, 8–26, 17–11
- Metolazone 15–9
- Mexilitine 5–62, 5–68
- Micro-enema 8–16
- Midazolam 6–28, 7–16, 14–6,  
    17–11, 18–7, 18–8
- Mini Mental State Examination 7–4
- Mirtazapine 5–66, 12–19, 12–23,  
    16–2
- MMSE. *See* Mini Mental State  
    Examination
- Modafinil 12–20, 12–24
- Monoamine oxidase inhibitors  
    12–21
- Morphine 5–11, 5–25, 5–30, 5–35,  
    5–47, 5–83, 17–12
- Multiple sclerosis (MS) 15–7
  - ataxia/tremor 15–8
  - pain, MS 15–7
  - spasticity 15–7
  - urinary problems 15–8
- Myoclonus 5–30, 5–32, 11–6, 12–19

## N

Naloxone 5-32, 17-12  
Narcotization. *See* Over-dosing  
Nasogastric tube (NG) 5-24, 8-22  
Nausea and vomiting 8-1  
    antiemetic 5-29, 8-3  
    assessment 8-6  
    bowel obstruction 8-22  
    clinical presentation 8-1  
    common causes 8-1  
    dopamine antagonism 5-29  
    emesis centres 8-3  
    management 8-8  
        5-HT<sub>3</sub> antagonists 8-11  
        antiemetic therapy 8-8  
        antihistamines 8-11  
        buscopan 8-12  
        cannabinoids 8-12  
        chlorpromazine 8-10  
        combination of antiemetics 8-13  
        corticosteroids 8-12  
        dimenhydrinate 8-2, 8-12  
        granisetron 8-11  
        haloperidol 8-10  
        hyoscine butylbromide 8-12  
        hyoscine hydrobromide 8-12  
        methotrimeprazine 8-10, 8-13  
        metoclopramide 8-9, 8-22, 17-11  
        olanzapine 8-11, 8-33  
        ondansetron 8-11  
        scopolamine 8-12, 17-14  
        tropisetron 8-11  
    metoclopramide 8-9, 8-22  
    neurotransmitters 8-3  
    refractory nausea 8-6, 8-12  
    reversible weight loss 8-29  
Nebulizer 5-24, 6-21  
Nefazodone 12-7, 12-20, 12-23  
Nerve blocks 5-73  
Neuroleptics 12-8  
    acute dystonia 7-15  
    akathisia 7-15  
    atypical neuroleptics 7-9, 7-10, 7-13, 8-11  
    chlorpromazine 6-26, 7-9, 8-10

    extrapyramidal side effects 7-9, 7-14, 8-9, 8-13  
    haloperidol 7-9, 7-11, 8-10, 17-9  
    loxapine 7-9, 7-12  
    methotrimeprazine 7-9, 7-12, 8-10, 17-10, 18-7  
    olanzapine 7-13, 8-11, 8-33, 12-28  
    Parkinsonism 7-15  
    quetiapine 7-9, 7-14, 12-8  
    risperidone 7-9, 7-14, 12-28  
Neurolytic procedures 5-62  
Neuropathic pain 5-60  
    anticonvulsants 5-64  
    baclofen 5-62, 5-68, 15-7  
    cannabinoids 5-71  
    capsaicin topical cream 5-62  
    carbamazepine 5-62, 5-65  
    celiac plexus block 5-62, 5-70, 5-73  
    clonazepam 5-62, 12-11  
    clonidine 5-62  
    cordotomy 5-62, 5-74  
    corticosteroids 5-57, 5-67  
    corticosteroids (for pain crises) 5-62  
    dextromethorphan 5-69  
    flecainide 5-62, 5-68  
    GABA agonists 5-62  
    gabapentin 5-62, 5-64, 15-7  
    IV lidocaine infusions 5-68  
    ketamine 5-62, 5-69  
    lamotrigine 5-62, 5-64, 5-66  
    lidocaine infusion 5-62, 5-68  
    lidocaine patch 5-62  
    local anesthetics 5-62, 5-68  
    mexilitine 5-62, 5-68  
    neurolytic procedures 5-55, 5-62  
    newer anticonvulsants 5-62, 5-65  
    NMDA antagonists 5-62, 5-69  
    nortriptyline 5-67, 12-17, 12-23  
    oral local anesthetics 5-62, 5-68  
    oxcarbazepine 5-62, 5-66  
    pregabalin 5-62, 5-66  
    rhizotomy 5-62

Intro ■

Contents ■

1 ■

Principles

2 ■

Ethics

3 ■

Communicate

4 ■

Expectancy

5 ■

Pain

6 ■

CP

7 ■

Delirium

8 ■

GI

9 ■

Hematology

10 ■

Metabolic

11 ■

Neurological

12 ■

Psychological

13 ■

Spiritual

14 ■

Emergencies

15 ■

Non-Cancer

16 ■

Miscellaneous

17 ■

Interventions

18 ■

Sedation

19 ■

Terminal

20 ■

Grief

Appendix ■

Refs ■

- sodium valproate 5–65, 11–3
  - tocainide 5–62, 5–68
  - topical capsaicin 5–67
  - topical lidocaine 5–67
  - topiramate 5–62, 5–66
  - tricyclic antidepressants 5–62
  - Neurosurgical radiological procedures 5–74
  - Neurotoxicity 5–29, 5–30
    - agitation 5–30
    - allodynia 5–30
    - confusion 5–30
    - hallucinations 5–30
    - hyperalgesia 5–30
    - management 5–31
    - myoclonus 5–30
    - opioid rotation 5–31
    - sedation 5–30
  - Neurotransmitters 8–3
  - Neutropenic infections 16–4
  - Newer anticonvulsants (lamotrigine, topiramate, oxcarbazepine, pregabalin) 5–62, 5–65
  - NG 8–34. See Nasogastric
  - NMDA antagonists 5–62, 5–69, 5–86
  - Nocturnal oximetry 15–2
  - Non-Benzodiazepine Anxiolytics 12–8
  - Non-cancer prognosis
    - Chronic Obstructive Airway Disease (COPD) 4–6
    - Congestive Heart Failure (CHF) 4–5
    - dementia 4–6
    - renal disease 4–7
    - stroke 4–7
  - Non-cancer – select issues
    - Amyotrophic Lateral Sclerosis (ALS) 15–1
    - COPD, end-stage 15–11
    - heart failure, end-stage 15–9
    - Multiple Sclerosis (MS) 15–7
  - Non-invasive Positive Pressure Ventilation (NPPV) 6–15, 15–2
  - Non-invasive ventilation 6–15, 15–3
  - Nortriptyline 5–67, 12–17, 12–23
  - NSAIDs 5–11, 5–13, 5–56, 5–80
    - celecoxib 5–13, 5–81, 5–82
    - diclofenac 5–80, 5–82
    - diflunisal 5–82
    - etodolac 5–82
    - ibuprofen 5–13, 5–80, 5–82
    - indomethacin 6–22, 5–82
    - ketoprofen 5–82
    - ketorolac 5–80, 5–82
    - naproxen 5–13, 5–80, 5–82, 16–4
    - piroxicam 5–82
  - Nursing Delirium Evaluation Scale (NuDESC) 7–5
  - Nursing home acquired pneumonia 16–12
- O**
- Obstructive airway disease 6–11
  - Octreotide 8–24, 9–20, 17–13
  - Oil retention enema 8–16
  - Olanzapine 5–76, 7–9, 7–13, 8–11, 8–33
  - Ondansetron 8–11, 16–2
  - Opioid equianalgesic dose
    - conversion table 5–47
  - Opioid neurotoxicity 5–30, 5–32, 5–51, 5–53
  - Opioid routes
    - fentanyl transdermal 5–38
  - Opioid rotation/switching 5–31, 5–44
    - opioid equianalgesic dose
      - conversion table 5–47
    - switching 5–43, 5–47
  - Opioids 5–17
    - 1st line 5–20
    - 2nd line 5–21
    - addiction 5–18, 5–19, 5–52
    - allergy 5–21, 5–83
    - breakthrough pain 5–5, 5–10, 5–14, 5–22, 5–26
    - buccal route 5–24, 5–49
    - constipation 5–28, 8–13
    - controlled-release 5–22, 5–37
    - dosing intervals 5–91
    - driving 5–20
    - duration of action 5–91

elderly 5-53, 5-56, 5-81, 7-7  
 end-of-dose failure 5-38, 5-40  
 epidural route 5-24, 5-32, 5-55, 5-73  
 fears and misapprehension 5-2, 5-17  
 fentanyl transdermal 5-38  
 gastrostomy tube (PEG) 5-24  
 incident pain 5-26  
 intramuscular (IM) 5-24  
 intraspinal route 5-24, 5-51, 5-55, 16-1  
 intrathecal route 5-24, 5-51, 5-55, 5-73  
 intravenous 5-23  
 long-acting formulation 5-22, 5-25, 5-38, 5-53  
 managing 5-26  
 methadone 5-69, 5-86, 5-90, 5-92  
 nasogastric 5-24, 6-26, 8-22  
 nausea 5-28, 8-1  
 nebulized route 5-24, 6-13  
 opioid formulations 5-88  
 opioid rotation/switching 5-44  
 Oral route (PO) 5-23  
 physical dependence 5-19  
 psychological dependence 5-19  
 psychostimulants 5-71, 7-16, 12-20  
 rectal route 5-24  
 renal impairment 5-8, 5-30, 5-51, 5-80, 5-81, 5-83  
 respiratory depression 5-27, 5-32, 5-33, 5-76  
 rotation 5-31, 5-44  
 route of administration 5-23  
 sedation 5-29  
 short-acting formulation 5-22  
 side effects 5-27, 5-51, 5-64, 5-80, 5-81  
 somnolence 5-29, 5-64  
 starting doses 5-25, 5-91  
 subcutaneous (SC) 5-23, 17-6  
 sublingual route 5-24, 5-50  
 substance abuse 5-52  
 sustained release 5-22

switching from PO to SC and IV route 5-23  
 titration of dose 5-33, 5-35  
 tolerance 5-19, 5-75  
 Opioid side effects 5-27  
 agitation 5-30  
 allodynia 5-30, 5-86  
 confusion 5-30, 7-4  
 constipation 5-28  
 hallucinations 5-30  
 hyperalgesia 5-30  
 myoclonus 5-30  
 nausea 5-28  
 neurotoxicity 5-29, 5-30  
 opioid rotation 5-31  
 over-dosing 5-32  
 rotation/switching 5-44  
 sedation 5-29, 5-30  
 somnolence 5-29  
 Opioid switching. See Opioid rotation  
 Oral fleets 8-17  
 Oral local anesthetics 5-62, 5-68  
 Organ and cornea donation 19-5  
 Osmotic laxative 8-15  
 Over-dosing 5-32  
 Oxcarbazepine 5-62, 5-66  
 Oxidized cellulose 9-17  
 Oxycodone 5-11, 5-21, 5-25, 5-47, 5-84, 17-13  
 Oxygen 6-13

**P**

Pacemakers 2-15, 14-3  
 Pain 5-1  
 adjuvant analgesics 5-54, 5-55, 5-56  
 assessment 5-4  
 barriers 5-2  
 basic principles 5-10  
 bone pain 5-54  
 breakthrough 5-26, 5-49  
 carbamazepine 5-15, 5-65  
 causes 5-2  
 classification 5-3  
 codeine 5-14  
 cognitive impairment 5-9, 5-30

Intro ■

Contents ■

1 ■ Principles

2 ■ Ethics

3 ■ Communicate

4 ■ Expectancy

5 ■ Pain

6 ■ CP

7 ■ Delirium

8 ■ GI

9 ■ Hematology

10 ■ Metabolic

11 ■ Neurological

12 ■ Psychological

13 ■ Spiritual

14 ■ Emergencies

15 ■ Non-Cancer

16 ■ Miscellaneous

17 ■ Interventions

18 ■ Sedation

19 ■ Terminal

20 ■ Grief

Appendix ■

Refs ■

- cytochrome P450 CYP 2D6 5–14
- examination 5–7
- incident 5–26
- initiating WHO 5–16
- investigations 5–8
- neuropathic 5–60
- NSAIDs 5–13, 5–56, 5–80, 5–82
- opioids 5–17
- pain scales 5–7
- poor prognostic factors 5–9
- prevalence 5–1
- propoxyphene 5–16
- somatizing 5–77
- tenesmus pain 8–45
- total pain 5–77, 13–1
- tramadol 5–15, 5–47, 5–88, 5–91
- visceral colic pain 5–70
- visceral pain 5–70
- WHO Ladder 5–11
- Palliative orthopaedic surgery 5–72
- Palliative Performance Scale (PPS)
  - A–8
- Palliative Prognostic Index (PPI)
  - 4–3, 4–4
- Palliative radiotherapy 5–71
  - cerebral metastases 11–5
  - external beam radiotherapy 5–71
- Palliative sedation 18–1
  - Calgary Guidelines 18–5
  - methotrimeprazine 18–7
  - midazolam 18–7, 18–8
  - phenobarbitone 18–10
  - propofol IV 18–10
  - refractory 18–1, 18–4
- Pamidronate 5–58, 5–60, 10–4
- Panic Disorder 12–5, 12–9
- Paracentesis 8–36, 8–37
- Paraneoplastic fever 16–3, 16–4
- Parkinsonism 7–15
- Paroxetine 12–22, 16–2, 16–3
- PEG tube 8–25, 8–34.
  - See gastronomy tube
- Pericardial effusion 6–3, 6–10, 6–18
- Peri-rectal cellulitis/abscess 16–10
- Peritoneovenous shunt 8–37
- Peritonitis 16–14
- Pharmacological Management of
  - Anxiety Disorder 12–6, 12–10
  - complicated grief 20–6
  - delirium 7–9
- Phenobarbitone 11–3, 18–10
- Phenothiazine 6–14, 7–9, 7–11, 8–10
- Phenytoin 5–62, 11–1, 14–8
- Physical dependence 5–19
- Platelets 8–37, 9–4, 9–20
- Pleural effusion(s) 6–9, 6–15, 15–10
- Pleurodesis 6–16
- PleurX 6–15, 8–37
- Pneumonia 6–10, 16–11
- Pneumothorax 6–9, 6–16, 17–22
- Polystyrene sulfonate 10–8
- Polyunsaturated Fatty Acids (PUFA)
  - 8–32
- Potassium Chloride 10–9, 17–13, 17–22
- Predicting life expectancy 4–1
- Pregabalin 5–62, 5–66
- Prognostication 4–3
  - Chronic Obstructive Airway Disease (COPD) 4–6
  - congestive heart failure (CHF) 4–5
  - dementia 4–6
  - Life Expectancy 4–1
  - Palliative Prognostic Index (PPI) 4–3
  - predicting life expectancy 4–1
  - renal disease 4–7
  - stroke 4–7
- Prognostication in non-cancer 4–5
- Pronouncement of death 19–4
- Propofol IV 18–10
- Propoxyphene 5–16
- Propranolol 12–9, 12–19, 15–6
- Prostaglandins E2 and F2 9–18
- Pruritis 16–1
  - antihistamines 16–2
  - cimetidine 16–2
  - doxepin 16–2
  - mirtazapine 16–2
  - ondansetron 8–11, 16–2
  - paroxetine 16–2

rifampicin 16–2  
 thalidomide 16–2  
 Pseudomembranous 8–18  
 Psychiatric 12–1  
 Psychiatrist 12–9, 12–15, 12–27,  
 18–6  
 Psychological 12–1  
 somatizing 5–77  
 total pain 5–77  
 Psychological dependence 5–19  
 Psychology  
 denial 3–21  
 dignity 3–27  
 dignity-conserving care 3–27  
 Psychostimulants 5–71, 7–16,  
 12–20, 12–24  
 Pulmonary artery/vein occlusion  
 6–3, 6–10  
 Pulmonary embolism 6–3, 6–10,  
 6–26, 9–14  
 Pyelonephritis 16–9

## Q

Quality of life 2–2, 2–9, 3–12  
 Quetiapine 7–9, 7–14, 12–8

## R

Radiotherapy 6–17, 11–5  
 cerebral metastases 11–5  
 external beam radiotherapy 5–71  
 systemic radionuclides  
 radiotherapy 5–72  
 Ranitidine 17–14  
 Recombinant human erythropoietin  
 9–4  
 Rectal route 5–24, 8–13  
 Refractory symptoms, sedation  
 18–1, 18–4  
 Refractory nausea 8–6, 8–12  
 Renal disease 4–7, 6–12, 6–20,  
 6–28  
 Renal impairment, opioids in 5–51  
 Respiratory congestion 6–23  
 atropine 6–25  
 glycopyrrolate 6–25  
 hyoscine butylbromide 6–25

hyoscine hydrobromide 6–25  
 Respiratory depression 5–27  
 Respiratory support 15–2  
 Rhizotomy 5–62  
 Rifampicin 16–2  
 Risperidone 7–9, 7–14  
 Route  
 buccal route 5–24  
 epidural route 5–24  
 gastrostomy tube (PEG) 5–24  
 intramuscular (IM) 5–24  
 intraspinal route 5–24  
 intrathecal route 5–24  
 intravenous (IV) 5–23  
 nasogastric (NG) 5–24  
 nebulized route 5–24  
 rectal route 5–24  
 subcutaneous (SC) 5–23  
 sublingual route 5–24  
 switching from PO to SC and IV  
 route 5–23  
 transdermal 5–24

## S

Sclerotherapy 9–18  
 Scopolamine 8–12, 8–16, 17–14  
 Secondary bacterial peritonitis  
 16–15  
 Sedation 5–29, 5–30, 18–1  
 Seizure(s) 11–1, 14–7  
 carbamazepine 11–3  
 phenobarbitone 11–3  
 phenytoin 11–1  
 sodium valproate 11–3  
 Selective serotonin reuptake  
 inhibitors (SSRI) 5–67, 12–18  
 Self-awareness 13–7  
 Senna-based laxative 8–15  
 Serotonin – norepinephrine  
 reuptake inhibitor (SNRI)  
 12–19  
 Sertraline 12–18, 12–22  
 Shortness of breath. See Dyspnea  
 SIADH 10–7  
 Sialorrhoea. See Drooling  
 Sikhism 13–13  
 Sodium phosphate 8–16, 8–17

Intro ■

Contents ■

1 ■

Principles

2 ■

Ethics

3 ■

Communicate

4 ■

Expectancy

5 ■

Pain

6 ■

CP

7 ■

Delirium

8 ■

GI

9 ■

Hematology

10 ■

Metabolic

11 ■

Neurological

12 ■

Psychological

13 ■

Spiritual

14 ■

Emergencies

15 ■

Non-Cancer

16 ■

Miscellaneous

17 ■

Interventions

18 ■

Sedation

19 ■

Terminal

20 ■

Grief

Appendix ■

Refs ■

- Sodium valproate 5–65, 6–26, 11–3
  - Somatizing 5–77
  - Somatostatin analogue 8–24
  - Somnolence 5–29
  - Soul pain 13–3
  - Spasticity 15–7
  - SPIKES 3–6
  - Spinal blocks 5–73
  - Spinal cord compression (SCC)
    - 11–3, 14–1
    - MRI scanning 14–3
  - Spiritual care 13–1, 13–5
  - Spirituality 13–1
    - dignity 13–8
    - FICA spiritual assessment tool 13–4
    - spiritual care 13–5
  - Spiritual pain 13–3
  - Starvation 8–28, 8–30
  - Status epilepticus 14–8
  - St. John's Wort 12–22
  - Stomas 8–43
  - Stomatitis 8–47
    - gingivostomatitis 8–48
  - Stool softener 8–15
  - Stroke 4–7
  - Subcutaneous hydration 17–19
  - Subcutaneous medicines 17–7
  - Subcutaneous (SC) injections 17–6
  - Sublingual route 5–24, 5–50
  - Substance abuse 5–52
  - Sucralfate suspension 9–17
  - Sufentanyl 5–50
  - Suffering 13–1
  - Sundowning 7–5, 7–10, 7–12
  - Superior vena cava syndrome (SVCS) 6–3, 6–10, 6–19, 14–8
  - Supportive counselling 12–4, 12–14
  - Suppositories 8–16, 8–17
  - Surgery 9–19, 11–5
    - kyphoplasty 5–74
    - palliative orthopaedic surgery 5–72
    - vertebroplasty 5–74
  - Surgical absorbable hemostatic dressings 9–17
  - Surgical management 5–72, 8–25
  - Survival 4–2
  - Sweats 16–3
    - excessive sweats 16–4
    - fever with rigors 16–4
    - neutropenic infections 16–4
    - paraneoplastic fever 16–4
  - Switching opioids 5–44
  - Switching opioids from PO to SC and IV route 5–23
  - Systemic radionuclides radiotherapy 5–72
- ## T
- Tamponade 6–3, 6–10, 6–18
  - TD fentanyl. *See* Transdermal fentanyl
  - Tenesmus 8–45
    - tenesmus pain 8–45
  - Terminal Phase 19–1
  - Terminal respiratory congestion 6–23, 19–1, 19–3
  - Thalidomide 8–33, 8–48, 16–2
  - The Nursing Delirium Screening Scale (NuDESC) A–13
  - Thiazide diuretic 15–9
  - Thoracentesis 6–15, 6–16
    - pleurodesis 6–16
    - PleurX 6–15
  - Thrombocytopenia 9–11, 9–19
  - Thrombocytosis 9–12
  - Thromboplastin 9–17
  - Thrombosis. *See* Venous thromboembolism
  - Tinzaparin 9–8, 9–10
  - Titration 5–33, 5–36
    - dyspnea 6–13, 15–4
    - long acting opioid 5–37
    - midazolam, sedation 18–9
    - morphine doses 5–35
    - short acting 5–22
  - Tocainide 5–62, 5–68
  - Tolerance, opioids 5–19
  - Topical capsaicin 5–67
  - Topical cocaine 9–17
  - Topical lidocaine 5–67
  - Topiramate 5–62, 5–66
  - Total pain 5–10, 5–77, 13–1
  - Total suffering 13–1
    - dignity 13–8

existential distress/issues 13–3  
 hope 13–9  
 soul pain 13–3  
 spirituality 13–1  
 spiritual pain 13–3  
 Tracheobronchial obstruction 6–9,  
 6–17  
     bronchoscopy 6–17  
     endobronchial stenting 6–17  
     radiotherapy 6–17  
 Tracheostomy 15–3  
 Trajectory 1–2, 2–1, 2–4, 4–1  
 Tramadol 5–11, 5–15, 5–47, 5–88,  
 5–91  
 Tranexamic acid (TA) 6–23, 9–16,  
 9–19  
 Transcutaneous arterial  
     embolization or balloons  
     9–19  
 Trazodone 12–20, 12–23, 12–25  
 Tricyclic antidepressants (TCA)  
     5–62, 5–66, 12–17  
 Tropisetron 8–11  
 Truth telling (disclosure) 3–1

## U

Uncomplicated grief 20–1, 20–3  
 Unfractionated heparin 9–6, 9–9  
 Uremia 5–29, 16–2  
 Urinary tract infections (UTI) 16–9  
 Urosepsis 16–10

## V

Variceal bleeding 9–18  
 Vasopressin 9–20  
 Vena caval filters 6–28, 9–11  
 Venlafaxine 5–66, 12–19, 12–22,  
 16–5  
 Venous thromboembolism 9–5  
     dalteparin 9–8  
     D-dimer 9–5  
     low molecular weight heparins  
     (LMWH) 9–6, 9–7  
     prophylaxis 9–10  
     dalteparin 9–10  
     heparin 9–10

prophylaxis  
     tinzaparin 9–10  
 pulmonary emboli 9–14  
 tinzaparin 9–8  
 unfractionated heparin 9–6  
 vena caval filters 6–28, 9–11  
 warfarin 9–9  
 Ventilator Withdrawal 17–2  
 Venting PEG tube 8–26  
 Vertebroplasty 5–74  
 Visceral colic pain 5–70  
 Visceral pain 5–70  
     corticosteroids 5–67  
 Vital capacity 15–2, 15–5  
 Vomiting 8–1. *See* Nausea

## W

Warfarin 9–9  
 Weight loss 8–27  
 WHO Ladder 5–11, 5–13  
     initiating 5–16  
     Step 1 drugs 5–13  
     Step 2 drugs 5–14  
     Step 3 drugs 5–16  
 Wish, versus using Hope 3–17  
 Withdrawing respirator support  
     17–2  
 Withdrawing treatments 2–11  
 Withholding treatments 2–11  
 Wound 16–16  
     charcoal dressings 16–17  
     exudative wounds 16–18  
     malodorous wounds 16–16  
     metronidazole 16–17  
     painful wounds 16–18

## X

Xerostomia 8–46

## Z

Zoledronic acid 5–58, 10–4, 17–19

Intro	■
Contents	■
1	■
Principles	
2	■
Ethics	
3	■
Communicate	
4	■
Expectancy	
5	■
Pain	
6	■
CP	
7	■
Delirium	
8	■
GI	
9	■
Hematology	
10	■
Metabolic	
11	■
Neurological	
12	■
Psychological	
13	■
Spiritual	
14	■
Emergencies	
15	■
Non-Cancer	
16	■
Miscellaneous	
17	■
Interventions	
18	■
Sedation	
19	■
Terminal	
20	■
Grief	
Appendix	■
Refs	■

